medigraphic.com

2014, Number 3

<< Back Next >>

Rev Cuba Endoc 2014; 25 (3)

Update on diagnostic and therapeutic management of paraganglioma

Hevia CME

Language: Spanish
References: 48
Page: 149-162
PDF size: 130.82 Kb.


ABSTRACT

Paraganglioma is a rare neuroendocrine tumor that may occur in several parts of the body. Roughly 97 % of these tumors are benign and can be excised through surgery whereas 3 % of them are malignant and cause distant metastasis. Almost 75 % are sporadic and the remaining 25 % are hereditary (more likely to be multiple and developed at early ages). They may be genetically predisposed and associated to family tumor syndromes such as type 2 multiple endocrine neoplasia, Von Hippel-Lindau syndrome and type 1 neurofibromatosis or specific mutations related to development of paragangliomas. When compared to the sporadic occurrence, the family presentation tends to appear at younger ages, with multiple locations. Owing to the low resource availability and the high cost of research, these tumors are difficult to be diagnosed in our conditions, so there may be failures in registering the real number of cases; this is the reason why it is always important to think on possible diagnostic confirmation when clinical suspicion of paraganglioma arises. Imaging studies and measurement of the non-physiological production of catecholamines may help in the diagnosis of this disease. The main therapeutical modalities are surgery, embolization and radiotherapy. The present review was intended to update this topic and to submit a treatment guideline.


REFERENCES

  1. Barakat MT, Meeran K, Bloom SR. Neuroendocrine tumours. Endocr-Relat Cancer. 2004;11:1-18.

  2. Omura M, Saito J, Yamaguchi K. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res. 2004;3(27):193-202.

  3. Neumann HP, Bausch B, McWhinney SR. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med. 2002;19(346):1459-66.

  4. Amar L, Bertherat J, Baudin E. Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol. 2005;34(23):8812-8.

  5. Brennan M, Macdonald J. Cancer of the Endocrine System. En: De Vita Jr, Vicent T, Samuel S. Cancer: Principies and practice of oncology. Philadelphia: J.B. Lippincott Company; 1985. p. 1198-201.

  6. Baysal BE, Ferrell RE, Willett-Brozick JE. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science. 2000;287:848-51.

  7. Hao HX, Khalimonchuk O, Schraders M. SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science. 2009;325:1139-42.

  8. Niemann S, Müller U. Mutations in SDHC cause autosomal dominant paraganglioma type 3. Nat Genet. 2000;3(26):268-70.

  9. Astuti D, Latif F, Dallol A. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet. 2001;1(69):49-54.

  10. Burnichon N, Brière JJ, Libé R. SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet. 2010;15(19):3011-20.

  11. Carney JA. Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney Triad): natural history, adrenocortical component, and possible familial occurrence. Mayo Clin Proc. 1999;6(74):543-52.

  12. Carney JA, Stratakis CA. Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney triad. Am J Med Genet. 2002;2(108):132-9.

  13. Qin Y, Yao L, King EE. Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat Genet. 2010;3(42):229-33.

  14. Plouin PF, Chatellier G, Fofol I. Tumor recurrence and hypertension persistence after successful pheochromocytoma operation. Hypertension. 1997;5(29):1133-9.

  15. Thompson LD. Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol. 2002;5(26):551-66.

  16. Nativ O, Grant CS, Sheps SG. The clinical significance of nuclear DNA ploidy pattern in 184 patients with pheochromocytoma. Cancer. 1992;11(69):2683-7.

  17. Wu D, Tischler AS. Lloyd RV. Observer variation in the application of the Pheochromocytoma of the Adrenal Gland Scaled Score. Am J Surg Pathol. 2009;4(33):599-608.

  18. Kimura N, Watanabe T, Noshiro T. Histological grading of adrenal and extraadrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors. Endocr Pathol. 2005;1(16):23-32.

  19. Linnoila RI, Keiser HR, Steinberg SM. Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Hum Pathol. 1990;11(21):1168-80.

  20. Tischler AS. Pheochromocytoma and extra-adrenal paraganglioma: updates. Arch Pathol Lab Med. 2008;8(132):1272-84.

  21. Lenders JW, Eisenhofer G, Mannelli M. Phaeochromocytoma. Lancet. 2005;366:665-75.

  22. Kopetschke R, Slisko M, Kilisli A. Frequent incidental discovery of phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma. Eur J Endocrinol. 2009;2(161):355-61.

  23. Motta-Ramirez GA, Remer EM, Herts BR. Comparison of CT findings in symptomatic and incidentally discovered pheochromocytomas. AJR Am J Roentgenol. 2005;3(185):684- 8.

  24. Young WF Jr. Clinical practice. The incidentally discovered adrenal mass. N Engl J Med. 2007;6(356):601-10.

  25. Mannelli M, Bemporad D. Diagnosis and management of pheochromocytoma during pregnancy. J Endocrinol Invest. 2002;6(25):567-71.

  26. Schenker JG, Granat M. Phaeochromocytoma and pregnancy-an updated appraisal. Aust N Z J Obstet Gynaecol. 1982;1(2):1-10.

  27. Ahlawat SK, Jain S, Kumari S. Pheochromocytoma associated with pregnancy: case report and review of the literature. Obstet Gynecol Surv. 1999;11(54):728-37.

  28. Keely E. Endocrine causes of hypertension in pregnancy-when to start looking for zebras. Semin Perinatol. 1998;6(22):471-84.

  29. Lenders JW, Pacak K, Walther MM. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA. 2002;11(287):1427-34.

  30. Sawka AM, Jaeschke R, Singh RJ. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab. 2003;2(88):553-8.

  31. Perry CG, Sawka AM, Singh R. The diagnostic efficacy of urinary fractionated metanephrines measured by tandem mass spectrometry in detection of pheochromocytoma. Clin Endocrinol (Oxf). 2007;5(66):703-8.

  32. Botella JI, Valero MA, Martín I, Álvarez F, García G, Luque M, et al. Manual de Diagnóstico y Terapéutica de Endocrinología y Nutrición. Madrid: Edit. Novo Nordisk; 2004. p.125.

  33. Young WF Jr. Phaeochromocytoma: how to catch a moonbeam in your hand. Eur J Endocrinol. 1997;1(136):28-9.

  34. Ilias I, Pacak K. Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab. 2004;2(89):479-91.

  35. Furuta N, Kiyota H, Yoshigoe F. Diagnosis of pheochromocytoma using [123I]- compared with [131I]-metaiodobenzylguanidine scintigraphy. Int J Urol. 1999;3(6):119-24.

  36. Cubeddu LX, Zarate NA, Rosales CB. Prazosin and propranolol in preoperative management of pheochromocytoma. Clin Pharmacol Ther. 1982;2(32):156-60.

  37. Prys-Roberts C, Farndon JR. Efficacy and safety of doxazosin for perioperative management of patients with pheochromocytoma. World J Surg. 2002;8(26):1037-42.

  38. Averbuch SD, Steakley CS, Young RC. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med. 1988;4(109):267-73.

  39. Druce MR, Kaltsas GA, Fraenkel M. Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001). Horm Metab Res. 2009;9(41):697-702.

  40. Jimenez C, Cabanillas ME, Santarpia L. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J Clin Endocrinol Metab. 2009;2(94):386-91.

  41. Joshua AM, Ezzat S, Asa SL. Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. J Clin Endocrinol Metab. 2009;1(94):5-9.

  42. Buscombe JR, Cwikla JB, Caplin ME. Long-term efficacy of low activity meta- [131I]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response. Nucl Med Commun. 2005;11(26):969-76.

  43. Scholz T, Eisenhofer G, Pacak K. Clinical review: current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab. 2007;4(92):1217-25.

  44. Gonias S, Goldsby R, Matthay KK. Phase II study of high-dose [131I] metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol. 2009;25(27):4162-8.

  45. Butters L, Kennedy S, Rubin PC. Atenolol in essential hypertension during pregnancy. BMJ. 1990;301(6752):587-9.

  46. Montan S, Ingemarsson I, Marsál K. Randomised controlled trial of atenolol and pindolol in human pregnancy: effects on fetal haemodynamics. BMJ. 1992;304(6832):946-9.

  47. Junglee N, Harries SE, Davies N. Pheochromocytoma in Pregnancy: When is Operative Intervention Indicated? J Womens Health (Larchmt). 2007;9(16):1362-5.

  48. Amar L, Servais A, Gimenez-Roqueplo AP. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Meta. 2005;4(90):2110-6.




2020     |     www.medigraphic.com